Akeso’s Ebdarokimab Receives Approval for Psoriasis Treatment in China

Akeso, Inc. ( (HK:9926) ) just unveiled an update.

Akeso, Inc. announced that the National Medical Products Administration of China has approved the new drug application for Ebdarokimab, a treatment for moderate to severe plaque psoriasis. This approval marks a significant advancement for Akeso as it is their first Class 1 new drug approved for autoimmune diseases and the second non-oncology drug to receive marketing approval. Ebdarokimab has shown positive short-term and sustained long-term efficacy, significant improvement in patients’ quality of life, and a good safety profile. The drug is poised to address the growing needs of the psoriatic population in China, offering a cost-effective and convenient treatment option.

More about Akeso, Inc.

Akeso, Inc. is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It specializes in developing innovative drugs, particularly in the field of autoimmune diseases and oncology, with a market focus on providing effective and patient-centric therapeutic solutions.

YTD Price Performance: 36.66%

Average Trading Volume: 12,473,628

Technical Sentiment Signal: Sell

Current Market Cap: HK$74.45B

For detailed information about 9926 stock, go to TipRanks’ Stock Analysis page.